H.C. Wainwright assumed coverage of Aethlon Medical (AEMD) with a Neutral rating and $1.50 price target The company is focused on developing and commercializing Hemopurifier, a medical device designed to deplete cancer-promoting exosomes or extracellular vesicles, the analyst tells investors in a research note. The firm is encouraged by Hemopurifier’s market potential, but sees no major catalysts in the next 12 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEMD:
- Aethlon’s Earnings Call: Clinical Progress Amid Financial Hurdles
- Aethlon Medical Reports Q4 Financial Results and Achievements
- Morning Movers: Li Auto lower following Q2 delivery guidance cut
- Aethlon Medical reports FY25 EPS ($8.58) vs. ($38.87) last year
- Aethlon Medical Reports Progress in Cancer Trials